April 14, 2021
Business News

Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development

CAMBRIDGE, Mass.–()–Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations. The senior appointments come just two months after the company announced over $230 million in Series B fundraising in January and will be key to advancing the company’s Gene Writing platform and accelerating development of multiple therapeutic programs.

“David, Hari and Lin all bring a wealth of strategic leadership and deep expertise to Tessera at an exciting time in our growth,” said…

Click here to view the original article.

Related Posts

You might also like ...

Personalized Loyalty Solutions Provider Exchange Solutions Raises Growth Funding
Polyneuron and University of Basel Awarded Grant of CHF 1.2M to Advance Novel Treatments to Support ABO-Incompatible Transplants
The Hundred Club of Massachusetts Announces Affiliation with Home Base